Eukaryotic translation initiation factor 4 gamma 1 (UniProt:Q04637)
CAT No: ta-050
Synonyms/Alias:Eukaryotic translation initiation factor 4 gamma 1 (719-727)
Eukaryotic translation initiation factor 4 gamma 1 (719-727) is a synthetic peptide fragment corresponding to amino acids 719 to 727 of the eIF4G1 protein, a central component of the eukaryotic translation initiation complex. As a key scaffold protein, eIF4G1 orchestrates the assembly of various initiation factors and ribosomal subunits, facilitating the recruitment of mRNA to the ribosome and regulating the efficiency of cap-dependent translation. The 719-727 region is of particular interest due to its involvement in protein-protein interactions critical for translation regulation, making this peptide fragment a valuable tool for dissecting molecular mechanisms underlying translational control in eukaryotic cells.
Protein-protein interaction studies: Researchers frequently employ the 719-727 peptide fragment of eIF4G1 to probe specific binding interfaces within the translation initiation machinery. By acting as a competitive inhibitor or binding probe, the peptide enables detailed mapping of interaction domains between eIF4G1 and its partners, such as eIF4E, eIF4A, and other regulatory proteins. This approach facilitates the elucidation of molecular determinants governing complex assembly and stability, supporting the development of mechanistic models for translation initiation.
Signal transduction research: The eIF4G1 (719-727) peptide is utilized to investigate signaling pathways that modulate translation initiation via post-translational modifications or dynamic interactions at this region. By introducing the peptide into in vitro or cell-based assays, scientists can assess the impact of phosphorylation events, proteolytic cleavage, or effector molecule binding on the function of the initiation complex. Such studies provide insight into how cellular signaling networks fine-tune protein synthesis in response to environmental cues or stress.
Peptide-based inhibitor screening: The defined sequence of the 719-727 fragment serves as a template for designing and evaluating small-molecule or peptide inhibitors targeting translation initiation. High-throughput screening assays often incorporate this peptide to identify compounds that disrupt critical contacts within the eIF4F complex, thereby modulating translational output. These experiments offer a focused platform for drug discovery efforts aimed at regulating protein synthesis in various biological contexts.
Epitope mapping and antibody validation: The unique amino acid stretch represented by eIF4G1 (719-727) is valuable for generating and validating antibodies specific to this region of the protein. The synthetic peptide can be used as an immunogen or as a standard in immunoassays to confirm antibody specificity and binding affinity. This application is essential for developing reliable detection reagents used in Western blotting, immunoprecipitation, or immunofluorescence studies targeting eIF4G1.
Structural and biophysical analysis: The isolated 719-727 peptide fragment provides a model system for studying conformational properties and secondary structure elements relevant to eIF4G1 function. Employing techniques such as NMR spectroscopy, circular dichroism, or crystallography, researchers can characterize the structural dynamics of this sequence in solution or in complex with binding partners. These investigations contribute to a deeper understanding of how local structural motifs influence the assembly and regulation of the translation initiation apparatus.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.